Chimeric antigen receptor (CAR) engineered T cells have demonstrated effective efficacy in the treatment of refractory hematological malignancies. CAR-T technology has become more and more mature and emerges as an important treatment option for various tumor indications. However, one of the challenges associated with CAR-T cell therapy is cytokine release syndrome (CRS).

Learn more about modular CA- T: https://www.creative-biola...
#health #biotech